Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators.

Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.

PMID:
20709233
2.

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252.

PMID:
16478899
3.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
4.

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group.

Lancet. 2006 Nov 11;368(9548):1660-72. Erratum in: Lancet. 2006 Nov 11;368(9548):1650.

PMID:
17098084
5.

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group.

Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370.

PMID:
15836887
6.

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

Hollander P.

Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32.

PMID:
17296341
7.

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group.

N Engl J Med. 2005 Nov 17;353(20):2121-34.

8.

Efficacy of rimonabant in obese patients with binge eating disorder.

Pataky Z, Gasteyger C, Ziegler O, Rissanen A, Hanotin C, Golay A.

Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):20-6. doi: 10.1055/s-0032-1329957. Epub 2012 Nov 12.

PMID:
23147209
10.

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A.

Lancet. 2007 Nov 17;370(9600):1706-13. Review. Erratum in: Lancet. 2008 Feb 16;371(9612):558.

PMID:
18022033
11.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

PMID:
18387931
12.

Cannabinoid type 1 receptor antagonists for smoking cessation.

Cahill K, Ussher MH.

Cochrane Database Syst Rev. 2011 Mar 16;(3):CD005353. doi: 10.1002/14651858.CD005353.pub4. Review.

PMID:
21412887
13.

Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.

O'Leary DH, Reuwer AQ, Nissen SE, Després JP, Deanfield JE, Brown MW, Zhou R, Zabbatino SM, Job B, Kastelein JJ, Visseren FL; AUDITOR investigators.

Heart. 2011 Jul;97(14):1143-50. doi: 10.1136/hrt.2011.223446. Epub 2011 May 24.

PMID:
21610270
14.

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group.

Eur Heart J. 2008 Jul;29(14):1761-71. doi: 10.1093/eurheartj/ehn076. Epub 2008 Apr 15.

15.

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A.

Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258.

PMID:
18227491
16.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

Christopoulou FD, Kiortsis DN.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. Review.

PMID:
21198716
17.

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators.

Lancet. 2008 May 24;371(9626):1761-8. doi: 10.1016/S0140-6736(08)60763-1.

PMID:
18502300
18.

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.

Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. doi: 10.1161/ATVBAHA.108.176362. Epub 2008 Dec 26.

19.

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

Cahill K, Ussher M.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005353. Review. Update in: Cochrane Database Syst Rev. 2011;(3):CD005353.

PMID:
17943852
20.

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

Cahill K, Ussher M.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005353. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD005353.

PMID:
17636794
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk